Cargando…

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan

This study investigated the “real-world” use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012–2014 for 264 consecutive eyes of 229 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yi-Sheng, Lee, Wan-Ju, Lim, Chen-Chee, Wang, Shih-Hao, Hsu, Sheng-Min, Chen, Yi-Chian, Cheng, Chia-Yi, Teng, Yu-Ti, Huang, Yi-Hsun, Lai, Chun-Chieh, Tseng, Sung-Huei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945845/
https://www.ncbi.nlm.nih.gov/pubmed/29748599
http://dx.doi.org/10.1038/s41598-018-25864-0
_version_ 1783322071815684096
author Chang, Yi-Sheng
Lee, Wan-Ju
Lim, Chen-Chee
Wang, Shih-Hao
Hsu, Sheng-Min
Chen, Yi-Chian
Cheng, Chia-Yi
Teng, Yu-Ti
Huang, Yi-Hsun
Lai, Chun-Chieh
Tseng, Sung-Huei
author_facet Chang, Yi-Sheng
Lee, Wan-Ju
Lim, Chen-Chee
Wang, Shih-Hao
Hsu, Sheng-Min
Chen, Yi-Chian
Cheng, Chia-Yi
Teng, Yu-Ti
Huang, Yi-Hsun
Lai, Chun-Chieh
Tseng, Sung-Huei
author_sort Chang, Yi-Sheng
collection PubMed
description This study investigated the “real-world” use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012–2014 for 264 consecutive eyes of 229 patients with nAMD, who applied for ranibizumab covered by national health insurance. A total of 194 eyes (73.5%) in 179 patients (65.5% men; mean ± standard deviation age 69.4 ± 10.7 years) were pre-approved for treatment. Applications for treatment increased year by year, but approval rates decreased during this time. The major causes of rejection for funding were diseases mimicking nAMD, including macular pucker/epiretinal membrane, macular scarring, dry-type AMD, and possible polypoidal choroidal vasculopathy. After completion of three injections in 147 eyes, visual acuity significantly improved, gaining ≥1 line in 51.8% of eyes and stabilising in 38.3% of 141 eyes in which visual acuity was measured. The 114 eyes approved with only one application had a better visual outcome than the 27 eyes approved after the second or third applications. In conclusion, ranibizumab is effective for nAMD; however, approval after the second or third application for national health insurance cover is a less favourable predictor of visual outcome.
format Online
Article
Text
id pubmed-5945845
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59458452018-05-17 Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan Chang, Yi-Sheng Lee, Wan-Ju Lim, Chen-Chee Wang, Shih-Hao Hsu, Sheng-Min Chen, Yi-Chian Cheng, Chia-Yi Teng, Yu-Ti Huang, Yi-Hsun Lai, Chun-Chieh Tseng, Sung-Huei Sci Rep Article This study investigated the “real-world” use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012–2014 for 264 consecutive eyes of 229 patients with nAMD, who applied for ranibizumab covered by national health insurance. A total of 194 eyes (73.5%) in 179 patients (65.5% men; mean ± standard deviation age 69.4 ± 10.7 years) were pre-approved for treatment. Applications for treatment increased year by year, but approval rates decreased during this time. The major causes of rejection for funding were diseases mimicking nAMD, including macular pucker/epiretinal membrane, macular scarring, dry-type AMD, and possible polypoidal choroidal vasculopathy. After completion of three injections in 147 eyes, visual acuity significantly improved, gaining ≥1 line in 51.8% of eyes and stabilising in 38.3% of 141 eyes in which visual acuity was measured. The 114 eyes approved with only one application had a better visual outcome than the 27 eyes approved after the second or third applications. In conclusion, ranibizumab is effective for nAMD; however, approval after the second or third application for national health insurance cover is a less favourable predictor of visual outcome. Nature Publishing Group UK 2018-05-10 /pmc/articles/PMC5945845/ /pubmed/29748599 http://dx.doi.org/10.1038/s41598-018-25864-0 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Chang, Yi-Sheng
Lee, Wan-Ju
Lim, Chen-Chee
Wang, Shih-Hao
Hsu, Sheng-Min
Chen, Yi-Chian
Cheng, Chia-Yi
Teng, Yu-Ti
Huang, Yi-Hsun
Lai, Chun-Chieh
Tseng, Sung-Huei
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
title Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
title_full Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
title_fullStr Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
title_full_unstemmed Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
title_short Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
title_sort real-world use of ranibizumab for neovascular age-related macular degeneration in taiwan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945845/
https://www.ncbi.nlm.nih.gov/pubmed/29748599
http://dx.doi.org/10.1038/s41598-018-25864-0
work_keys_str_mv AT changyisheng realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan
AT leewanju realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan
AT limchenchee realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan
AT wangshihhao realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan
AT hsushengmin realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan
AT chenyichian realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan
AT chengchiayi realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan
AT tengyuti realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan
AT huangyihsun realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan
AT laichunchieh realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan
AT tsengsunghuei realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan